Digital Therapeutics Archives

Blog

ISPOR 2023 Trinity Panel: Enabling Patient Access to Digital Therapeutics – The Optimal Approach?

June 21, 2023

Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team, moderated an exciting conversation at ISPOR 2023 Global in Boston earlier this month. Monica spoke with Lisa Marsch, Ph.D., Benjamin Parcher, PharmD, MS, and Fulton Velez,...

Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team presenting at ISPOR 2023

Blog

Global Evidence Requirements to Launch a Digital Health Technology

November 12, 2021

In this article, Trinity analyzed existing guidelines and evaluation frameworks for digital health technologies, including mobile health (mHealth) applications, to identify key evidence requirements and areas that should be considered in the clinical assessment of digital health services.

Blog

Are Current Reimbursement Options for Opioid Use Disorder DTx Causing a Barrier to Widespread Adoption in the USA?

November 9, 2021

In 2020, Trinity assessed three applications developed to treat Opioid Use Disorders (OUD) (e.g., reSET-O, Connections, DynamiCare) through the lens of ICER conducting a cost-effectiveness evaluation. Only a year later, several more health tech startups have adopted a preventative outlook and seek...

Blog

Kaiser Integrates DTx Into the Behavioral Health Treatment Paradigm at No Extra Cost After a Clinician Referral

February 19, 2021

Written by Tom Rutkowski, Patrick Buck, Kate Watkins, and Cameron Lam

Blog

ICER Released First Cost-Effectiveness Assessment for a Digital Therapeutic (DTx)

November 3, 2020

Three digital health technologies have been developed to treat opioid use disorder (OUD). These applications, reSET-O (Pear Therapeutics), Connections (Chess Health) and DynamiCare (DynamiCare Health) [...]

Blog

FDA Launches the Digital Health Center of Excellence

October 15, 2020

Written by Tom Rutkowski, Jay Galli, and Kate Watkins

Blog

Access and Reimbursement: Access to Digital Therapeutics in a Post-COVID-19 World

July 14, 2020

Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake. Payers are still at very different stages in their acceptance of DTx, and...